Transparency vs. Smoke and Mirrors: Clinical Trials Debate

December 22, 2015 Peter J. Pitts

 

broken-mirror.jpg

The debate around clinical trial transparency is certainly nothing new. But is the answer, as some call for, "more transparency and oversight?"

I say it’s just not that simple.

As the former senior government official in charge of clinicaltrials.gov, I think it’s important to look at the facts – and the numbers.  When it comes to the clinical trial looking glass, smart transparency must replace the smoke and mirrors currently in vogue.

Read my full article in the The Morning Consult, where I ask key questions and examine critical issues surrounding the debate. 

Be sure to read on about different clinical trial best practices in the YourEncore Thought Leadership blog.

Peter J. Pitts. Executive Partner for YourEncore, President - Center for Medicines in the Public Interest, Former FDA Associate Commissioner.

Watch the Regulatory Convergence & Divergence Expert Panel Discussion

 

Previous Article
6 Must-Ask Questions Before Adding New Biomarkers to Your Clinical Trial Protocols
6 Must-Ask Questions Before Adding New Biomarkers to Your Clinical Trial Protocols

During my 18 years at a major pharmaceutical company I initiated and managed the introduction of...

Next Article
Social Media & Postmarketing Surveillance - Signal vs. Noise
Social Media & Postmarketing Surveillance - Signal vs. Noise

New technologies that support postmarketing patient communication and safety surveillance can produce a mo...